Skip to main content

Piloting Melanoma Research and Local Cancer Care: An Oncology Data Advisor® Editorial Board Spotlight Interview With Richard Carvajal, MD

Oncology Data Advisor® · Piloting Melanoma Research and Local Cancer Care With Richard Carvajal, MD This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-...

Continue reading

Exploring the TALAPRO-2 Study of Talazoparib and Enzalutamide in Prostate Cancer: Stephen Freedland, MD, and Neeraj Agarwal, MD

In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance. 

Continue reading

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.

Continue reading

Great American Smokeout: The Link Between Smoking and Prostate Cancer With Stephen Freedland, MD

In honor of the Great American Smokeout, Oncology Data Advisor sat down with Stephen Freedland, MD, the Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center, to discuss the impact that smoking has on prostate cancer, as well as to help raise awareness around smoking and share resources for those who are trying to quit.  

Continue reading

Prostate Cancer Awareness Month With Ulka Vaishampayan, MD

Oncology Data Advisor® · Prostate Cancer Awareness Month With Ulka Vaishampayan, MD In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.   Oncology Data Advisor: Welcome to Oncology D...

Continue reading

Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD

In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  

Continue reading

Introducing the Oncology Data Advisor® Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows With Samuel Kareff, MD, MPH

Oncology Data Advisor® · Fellows Forum: A Valuable Resource for Hematology/Oncology Fellows Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, discusses the educational topics that he is looking forward to sharing his insights on as a Fellows Forum...

Continue reading

Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD

Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial and socioeconomic disparities experienced by patients in the chronic lymphocytic leukemia (CLL) community oncology and hematology setting, how to comba...

Continue reading

Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma With Hans Lee, MD

Oncology Data Advisor® · Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Hans Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Hans Lee, the Director of Multiple Myeloma Clinical Research at MD Anderson, presented his team's research from the LINKER-MM1 study, which sought to evaluate response patterns of linvoseltamab for relapsed/refractory multiple myeloma. Later, Dr. Lee sat down with Oncology Data Advisor to further discu...

Continue reading

Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD

Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 study which investigated odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Oncology...

Continue reading

Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD

Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and presentation regarding the ELM-2 trial which studied circulating tumor DNA (ctDNA) as a predictive biomarker with odronextamab for follicular lymphoma (F...

Continue reading

Streamlining the Pathology Workflow Through Artificial Intelligence With Waqas Haque, MD, MPH, and Leif Honda of TriMetis

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.  

Continue reading

Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD

At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  

Continue reading

Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD

In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  

Continue reading

Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD

Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her presentationregarding real-world outcomes of brexucabtagene autoleucel (brexu-cel) in patients with relapsed/refractory mantle cell lymphoma.   Onc...

Continue reading

Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial With Ibrahim Aldoss, MD

Oncology Data Advisor® · Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial: Ibrahim Aldoss, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ibrahim Aldoss, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, to further discuss his presentation investigating revumenib for patients with relapsed/refractory histone-lysine N-methyltransfera...

Continue reading

Streamlining the Pathology Workflow Through Artificial Intelligence With Waqas Haque, MD, MPH, and Leif Honda of TriMetis

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.  

Continue reading

Predicting Immune-Related Adverse Events Through Machine Learning With OncoHost: Dr. Waqas Haque, Dr. Matthew Hadfield, and Dr. Ofer Sharon

In this first episode of Oncology Data Advisor's new podcast series, "Exploring Artificial Intelligence in Cancer Care," Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients' probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost's novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.  

Continue reading

Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD

Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hematologic malignancies stay local. In this podcast episode, Dr. Patel-Donnelly sits down with Oncology Data Advisor to discuss her session, share some o...

Continue reading

Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD

Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long-term follow up results from the ELEVATE-TN study, which investigated acalabrutinib plus or minus obinutuzumab for previously untreated patients with ...

Continue reading